However, rechallenge with an anti–PD-1 antibody in 4 patients out of 21 with previous liver toxicity under anti–CTLA-4 and anti–PD-1 combination therapy did not cause a recurrence of hepatitis. This evidence concerns the gene CTLA4 and hepatitis A virus infection.